Renal denervation: a key approach to hypertension and cardiovascular disease
- PMID: 38961280
- DOI: 10.1038/s41440-024-01776-7
Renal denervation: a key approach to hypertension and cardiovascular disease
Abstract
Sympathetic activation plays a critical role in the development of hypertension and cardiovascular disease, including heart failure and arrhythmias. Renal nerves contribute to the regulation of blood pressure and fluid volume through renal sympathetic efferent nerves, and to the modulation of sympathetic outflow through renal sensory afferent nerves. Previous studies including ours suggest that selective afferent renal denervation with preservation of efferent renal nerves can significantly decrease central sympathetic outflow in animal models of hypertension with renal damage. In Dahl salt-sensitive rats fed high salt diet from an early age, a model of hypertensive heart failure, this central sympathoinhibition by afferent renal denervation may attenuate the development of heart failure without significant blood pressure reduction. Accumulating clinical evidence supports the efficacy of renal denervation as an antihypertensive treatment. However, it remains important to clarify the appropriate indications and predictors of responders to renal denervation in the treatment of hypertension. Several clinical studies suggest beneficial effects of renal denervation in patients with heart disease, with or without hypertension, although most were not sham-controlled. In particular, some clinical studies have demonstrated that renal denervation reduces the incidence of atrial fibrillation or cardiovascular events even without a significant antihypertensive effect. It is essential to accumulate more insightful data in patients undergoing renal denervation, to establish the efficacy of renal denervation in patients with cardiovascular disease in the clinical setting, and to elucidate the therapeutic mechanisms of renal denervation and the renal nerves-linked pathophysiology of cardiovascular disease in basic research. This review outlines the effects of renal denervation on sympathetic activity and organ damage in animal models of hypertension and hypertensive heart failure, including our own data. Beyond the antihypertensive effects, the beneficial effects of renal denervation on cardiovascular disease are also discussed based on clinical studies. Several animal and clinical studies suggest the cardioprotective effects of renal denervation even in the absence of significant blood pressure reduction, probably due to its sympathoinhibitory effects.
Keywords: Cardiovascular disease; Heart failure; Hypertension; Renal denervation; Sympathetic nervous system.
© 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Similar articles
-
Renal denervation for hypertensive heart disease and atrial fibrillation.Hypertens Res. 2024 Oct;47(10):2665-2670. doi: 10.1038/s41440-024-01755-y. Epub 2024 Jun 14. Hypertens Res. 2024. PMID: 38877310 Review.
-
Renal denervation: basic and clinical evidence.Hypertens Res. 2022 Feb;45(2):198-209. doi: 10.1038/s41440-021-00827-7. Epub 2021 Dec 17. Hypertens Res. 2022. PMID: 34921299 Review.
-
Reinnervation following catheter-based radio-frequency renal denervation.Exp Physiol. 2015 Apr 20;100(5):485-90. doi: 10.1113/expphysiol.2014.079871. Epub 2015 Jan 22. Exp Physiol. 2015. PMID: 25573386 Review.
-
Renal Afferents.Curr Hypertens Rep. 2016 Sep;18(9):69. doi: 10.1007/s11906-016-0676-z. Curr Hypertens Rep. 2016. PMID: 27595156 Free PMC article. Review.
-
Renal sympathetic denervation: applications in hypertension and beyond.Nat Rev Cardiol. 2013 Aug;10(8):465-76. doi: 10.1038/nrcardio.2013.89. Epub 2013 Jun 18. Nat Rev Cardiol. 2013. PMID: 23774592 Review.
Cited by
-
Report on the Joint Symposium of the Korean Society of CardioMetabolic Syndrome (KSCMS) and the Japanese Society of Hypertension (JSH) at the 8th Asia-Pacific CardioMetabolic Syndrome (APCMS) Congress in Seoul.Hypertens Res. 2025 Jul 29. doi: 10.1038/s41440-025-02310-z. Online ahead of print. Hypertens Res. 2025. PMID: 40731079 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical